•Reed Jobs' venture firm, Yosemite, specializing in oncology, is rapidly expanding its efforts to build biotech companies from early academic research.
•Artificial intelligence has become a "huge part" of Yosemite's strategy, significantly accelerating opportunities in drug discovery and clinical trial design.
•Yosemite employs a unique hybrid funding model, blending no-strings-attached philanthropy with traditional venture capital to de-risk novel cancer therapies.
•BMW i Ventures, the automaker's VC arm, launched a new $300 million fund specifically targeting early to Series B AI startups.
•The fund will focus on agentic AI, physical AI (robotics, autonomous vehicles), industrial software, advanced materials, and manufacturing/supply chain tech.
•This strategic investment reflects BMW's view that AI is a foundational technology poised to transform automotive design, production, and engineering workflows, like the Synera example that cuts weeks...
•Reed Jobs' venture firm, Yosemite, specializing in oncology, is rapidly expanding its efforts to build biotech companies from early academic research.
•Artificial intelligence has become a "huge part" of Yosemite's strategy, significantly accelerating opportunities in drug discovery and clinical trial design.
•Yosemite employs a unique hybrid funding model, blending no-strings-attached philanthropy with traditional venture capital to de-risk novel cancer therapies.
•BMW i Ventures, the automaker's VC arm, launched a new $300 million fund specifically targeting early to Series B AI startups.
•The fund will focus on agentic AI, physical AI (robotics, autonomous vehicles), industrial software, advanced materials, and manufacturing/supply chain tech.
•This strategic investment reflects BMW's view that AI is a foundational technology poised to transform automotive design, production, and engineering workflows, like the Synera example that cuts weeks...
